[Meningococcal serogroup B vaccines].

Centre Hospitalier de Versailles, 177, rue de Versailles, 78150 Le Chesnay, France.
Archives de P├ędiatrie (Impact Factor: 0.41). 09/2012; 19 Suppl 2:S65-9.
Source: PubMed


The diversity and antigenic variability of Neisseria meningitidis serogroup B strains around the world has been a major challenge to developing a vaccine with broad coverage. Outer-membrane vesicle vaccines appear to be safe and effective but are strain-specific vaccines and used in delimited areas. Also, recombinant protein vaccines such as factor H binding protein, given alone or in combination with others antigens have been developed and may be effective against the majority of group B strains.

1 Follower
13 Reads